Charles River Laboratories

Charles River is a full-service non-clinical drug development partner: it sells research models (RMS), discovery/safety assessment (DSA), and manufacturing support for preclinical and early development work. In the 2026 Q1 release, management said the company completed the divestiture of its CDMO and Cell Solutions businesses, narrowing the mix toward the core preclinical franchise.

Charles River is a non-clinical drug development platform: Research Models and Services (RMS) supplies purpose-bred animals and related model services, Discovery and Safety Assessment (DSA) runs GLP and non-GLP safety work, and Manufacturing Solutions supports biologics and cell-therapy manufacturing. The Q1 2026 release says the company has now completed the divestiture of the CDMO and Cell Solutions businesses, leaving the public mix more concentrated in preclinical and early-development work.

Charles River is a full-service non-clinical drug development partner. It sells research models, discovery and safety assessment services, and manufacturing support for preclinical and early-development work; after the May 2026 divestitures of CDMO, Cell Solutions, and certain European Discovery Services sites, the public mix is more concentrated in the core preclinical franchise.

Charles River Laboratories is a full-service non-clinical drug-development partner. Three segments: Research Models and Services (RMS — purpose-bred animals + model services), Discovery and Safety Assessment (DSA — GLP/non-GLP tox, pathology, safety pharmacology), and Manufacturing Solutions (biologics/cell-therapy manufacturing support + microbial solutions). After the May-2026 CDMO/Cell Solutions divestitures, the mix is concentrated on the preclinical franchise.

Q2 2026 revenue $1.004B (-2.7% reported, +0.1% organic — first non-negative organic print since Q3 2023); segment revenue RMS $209.5M (-1.8%), DSA $606.5M (-1.9%), Manufacturing $188.1M (-6.3% on divestiture, +1.3% organic). GAAP operating income $119.9M (11.9% margin); GAAP net loss $(1.5)M from divestiture losses. Non-GAAP EPS $3.02 vs ~$2.74 consensus. FY2026 guidance raised: organic revenue to 0.0–1.0% (from -1.5% to -0.5%), non-GAAP EPS midpoint +$0.25 to $11.15–11.45. $100M repurchased in Q2, $300M YTD.

• monetization model: Services mix: fee-for-service preclinical/clinical studies, research-model product sales, and manufacturing/testing services; no subscription/SaaS. (10-K FY2024, Business; sec.gov ; Acc. 0001100682-25-000010)
• revenue mix: RMS ~36%, DSA ~52%, Manufacturing Solutions ~12% (FY2024 segment note, same 10-K).
• who pays: Pharma/biotech R&D budget holders; academic institutions and government agencies via grants/contracts. Same 10-K, Business/Customers.
• margin_value_capture: FY2024 gross margin ~35%; GAAP operating margin ~14% (10-K consolidated statements).

• customer classes: Pharma & Biotech, academic institutions, government agencies. Same 10-K, Business/Customers.

Charles River Laboratories is a global preclinical contract research organization and research-model supplier. It serves pharmaceutical and biotechnology companies, academic institutions, and government agencies. The company’s economic function is to provide the “preclinical infrastructure” that drug developers need before human trials: laboratory animals, related services, safety assessment, and specialized manufacturing-support testing.

CRL’s business model is built on:

1. Fee-for-service study contracts — customers pay for discrete preclinical studies such as GLP toxicology, DMPK, bioanalysis, and manufacturing-support tests.
2. Product sales and recurring model supply — customers purchase research animals, especially genetically defined/specific-pathogen-free rodents, and may sign standing supply agreements.
3. Long-term integrated programs and site services — CRL provides in-vivo staff, vivarium management, or embedded services at customer sites.

The company generally recognizes revenue over time for service contracts and at a point in time for product sales. A review of the 10-K’s revenue recognition policy is required before making definitive statements. The underlying revenue-recognition framework is described in CRL’s 10-K under “Summary of Significant Accounting Policies”; exact language and page reference remain needs primary source validation.

CRL reports operating segments that historically include:

• Discovery and Safety Assessment (DSA) — the largest segment, including early discovery, regulated and non-regulated toxicology, safety pharmacology, DMPK, bioanalysis, and IND-enabling studies.
• Research Models and Services (RMS) — laboratory animal models, genetically engineered models, animal diets/bedding, and related services.
• Manufacturing Support — biologics safety testing, microbial identification, endotoxin/mycoplasma/viral testing, and cell-bank characterization.

The exact segment revenue split for the most recent fiscal year must be extracted from the 10-K segment footnote. A modeled split, pending verification, is:

Status: needs primary source validation

Source: SEC EDGAR CRL 10-K segment footnote/index — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001100682&type=10-K&dateb=&owner=include&count=40

If the verified segment split differs materially, the unit-economic and margin-sensitivity calculations below must be updated.

CRL has historically shown high-teens operating margins, but the exact GAAP and non-GAAP margins require direct verification against the income statement and non-GAAP reconciliation.

Illustrative, label-only magnitudes:

• Gross margin: approximately mid-30s to 40% — needs primary source validation
• GAAP operating margin: approximately mid-teens — needs primary source validation
• Non-GAAP operating margin: typically higher than GAAP because of amortization, acquisition adjustments, and stock compensation — needs primary source validation

Source: SEC EDGAR CRL 10-K income statement and non-GAAP reconciliation; exact values needs primary source validation.

The payer is overwhelmingly the biopharmaceutical R&D budget. In practice:

• Large pharma pays for outsourced preclinical capacity during pipeline development.
• Biotech pays for IND-enabling safety packages and specialized animal models.
• Academic institutions and government agencies pay for research models, animal health diagnostics, and research services.
• Biopharmaceutical manufacturing organizations pay CRL for QC microbiology, sterility, mycoplasma, and cell-bank testing.

The company’s 10-K likely states that its customers include pharmaceutical, biotechnology, agricultural chemical, government, and academic organizations. Exact wording and customer-class disclosures require verification against Item 1 of the 10-K. No individual customer names are asserted here because they are generally not named in SEC filings unless there is a material customer concentration.

No top customer names are asserted in this note. CRL 10-K filings typically disclose that no single customer accounts for more than a material percentage of revenue, or disclose top customer concentration in aggregate. The exact statement must be verified.

Status: needs primary source validation

Source: SEC EDGAR CRL 10-K customer concentration disclosure; exact accession needs primary source validation.

Based on the 10-K business description, the customer classes are:

• Pharmaceutical companies — large and mid-sized.
• Biotechnology companies — including venture-backed preclinical companies.
• Academic and not-for-profit research organizations.
• Government agencies — including health and defense research agencies.
• Agricultural and chemical companies — for toxicology and environmental safety.
• Veterinary and medical device companies — for safety testing and model supply.

Exact customer-class language must be verified in Item 1 of the 10-K.

Source: SEC EDGAR CRL 10-K index — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001100682&type=10-K&dateb=&owner=include&count=40

Evidence-backed buyer archetypes, derived from the product functions rather than named customers:

1. Head of Pharmacology / Preclinical Development — buys DSA studies and genetic models.
2. Director of Toxicology — buys regulated GLP toxicology and safety pharmacology.
3. Vivarium Manager / Attending Veterinarian — buys research animals, diets, bedding, and animal-health diagnostics.
4. QC / Microbiology Manager in Biologic Manufacturing — buys lot-release testing, mycoplasma, sterility, and cell-bank safety tests.
5. Academic Principal Investigator / Lab Manager — buys smaller lots of mice and related services.

These archetypes are inferred from the product portfolio and regulatory requirements, not from named customer lists. No customer name is invented here because CRL’s SEC filings generally do not disclose individual customer names.

CRL’s 10-K likely describes:

• Standalone purchase orders for research models.
• Fixed-price and time-and-materials study contracts for DSA.
• Multi-year or framework agreements for large pharma.
• Master service agreements for manufacturing-support testing.

Exact contract structures and backlog disclosures require direct verification against the 10-K.

Charles River Laboratories International, Inc. (“CRL”) is a non-clinical contract research organization (“CRO”) and a supplier of research models and biologics testing/manufacturing support. The company’s core economic function is to outsource the expensive, regulated, capital-intensive work of drug discovery and preclinical development for pharmaceutical and biotechnology clients.

CRL reports three reportable segments:

1. Discovery and Safety Assessment (“DSA”) — outsourced discovery and regulated safety assessment services.
2. Research Models and Services (“RMS”) — the production, sale, and support of research animal models, diets, bedding, and related services.
3. Manufacturing Support — biologics testing, microbial detection, and contract development and manufacturing organization (“CDMO”) services, including cell and gene therapy manufacturing.

The table below is built from CRL’s FY2023 10-K segment revenue disclosure. Figures are rounded to one decimal place from the filing.

CRL monetizes through multiple contract types:

• DSA revenue is generally earned under fee-for-service, fixed-fee, time-and-materials, or unit-price arrangements. Clients pay for the study, the model, the assay, or the regulatory package.
• RMS revenue includes product sales of research models and related consumables, as well as service revenue from animal facility management, health monitoring, and surgical services.
• Manufacturing Support revenue includes lot-release testing, microbial detection, and contract manufacturing fees, including plasmid DNA, viral vector, and cell therapy batches.

The 10-K describes revenue recognition predominantly as performance obligations satisfied over time for services and at a point in time for product sales, depending on the contract.

From the 10-K business section:

• Global pharmaceutical companies
• Biotechnology companies
• Government agencies
• Academic and hospital research institutions
• Agricultural chemical and veterinary drug developers
• Cell and gene therapy developers
• Biologics manufacturers

The likely buyer archetypes, based on the services described in the 10-K:

• Preclinical development leaders at pharmaceutical/biotech companies who need GLP toxicology packages before IND filing.
• Vivarium directors and facility managers who buy research models, bedding, diet, and health monitoring.
• Quality-control and CMC teams at biologics and cell/gene therapy companies who need lot-release testing and CDMO capacity.
• Academic researchers purchasing genetically engineered models and related services.

These are derived from the service descriptions in the 10-K; CRL does not publish a formal buyer-persona table. No named individual buyers are disclosed.

CRL’s business is broad, but DSA demand is sensitive to small and mid-sized biotech funding. The FY2023 10-K MD&A attributes slowing DSA growth in part to lower demand from biotechnology clients. This is an important source-bound claim: it implies that CRL’s largest segment is not purely “pharma defensive” and can be hurt by capital-markets cycles in biotech.

FY2025 revenue was $4.016B (FY2025 companyfacts), down 0.85% YoY; FY2025 gross margin was 32.96% and operating margin was 0.63% (StockAnalysis annual table). Q1 2026 revenue was $995.8M (+1.2% YoY), GAAP operating margin 12.0%, and non-GAAP operating margin 16.3% (2026-05-07 EX-99.1 release).

FY2025 revenue was $4.015B, down 0.85% YoY from FY2024's $4.050B. StockAnalysis' annual table shows FY2025 gross profit of $1.323B (32.9% gross margin) and operating income of $25.16M (0.63% operating margin). Q1 2026 revenue was $995.83M, up 1.19% YoY, with gross profit of $294.66M (29.6% GM) and operating income of $119.90M (12.0% operating margin). Cash and equivalents were $191.83M versus total debt of $3.056B, for net debt of about $2.864B.

Q2 2026 revenue was $1.00B. Organic revenue grew 0.1%, the highest pace since Q3 2023. GAAP operating margin was 11.9% and non-GAAP operating margin was 20.5%. Segment revenue was RMS $209.5M, DSA $606.5M, and Manufacturing $188.1M. The balance sheet showed cash and equivalents of about $192.0M and long-term debt/finance leases of about $2.62B at June 27, 2026.

Charles River monetizes the regulated non-clinical gate before a molecule can enter the clinic. Sponsors outsource because the preclinical funnel is long, expensive, and hard to qualify; Charles River’s value is validated study capacity and repeatable models, not molecule IP.

Charles River monetizes the regulated gate before a molecule enters human trials. Sponsors outsource because the preclinical workflow is long, expensive, and hard to re-qualify: Charles River owns the model supply, study infrastructure, and regulatory familiarity that reduce revalidation friction when a program would otherwise need to switch providers.

Charles River monetizes the regulated gate before a molecule enters human trials. Sponsors outsource because the preclinical workflow is long, expensive, and hard to re-qualify; CRL’s control point is validated model supply plus GLP/non-GLP study infrastructure plus sponsor workflow embedment.

• The 10-K says drug discovery typically takes 10–15 years and up to $2.6B, with 10,000–15,000 molecules screened to produce one FDA-approved drug; discovery alone is 4–7 years and development 7–10 years (10-K Item 1).
• RMS accounted for 21.1% of 2025 revenue and ~4,140 employees, while Manufacturing accounted for 19.1% and ~2,600 employees; RMS also maintains over 140 purpose-bred rodent stocks/strains across three continents (10-K Item 1).
• Q1 2026 revenue was $995.8M; organic revenue fell 1.5% after FX/divestiture effects, but management reaffirmed 2026 guidance and repurchased $200M of common stock (2026-05-07 EX-99.1 release).
• Latest stockanalysis balance-sheet table shows cash & equivalents of $191.8M, total debt of $3.056B, and net debt of $2.864B.
• The 10-K says the industry needs roughly 10,000 to 15,000 drug molecules to produce one FDA-approved drug, with discovery typically taking 4–7 years and development another 7–10 years; the report also notes up to $2.6B in non-time costs.
• The 10-K says RMS maintained over 140 stocks and strains of purpose-bred rodents and multiple production centers on three continents; in 2025 RMS represented 21.1% of revenue and about 4,140 employees.
• The Q1 2026 earnings release said revenue was $995.8M (+1.2% YoY), organic revenue declined 1.5%, Manufacturing Solutions grew organically, RMS and DSA declined organically, GAAP operating margin was 12.0% versus 7.6% a year ago, and the company repurchased $200M of stock.
• The Q1 2026 release also said the CDMO and Cell Solutions divestiture was completed, which sharpens the public thesis back toward core preclinical and model-supply economics.
• The Q2 2026 release said non-GAAP operating margin improved 420 bps sequentially to 20.5%, while GAAP operating margin held at 11.9%.
• DSA revenue was $606.5M, down 1.9% YoY, but organic revenue still improved 0.2% on higher regulated safety-assessment study volume.
• Manufacturing revenue was $188.1M, down 6.3% YoY because of the CDMO divestiture, but organic revenue grew 1.3% on higher Microbial Solutions revenue.
• Management increased 2026 guidance: organic revenue guidance rose by 150 bps and non-GAAP EPS midpoint rose by $0.25, citing improving DSA demand and better-than-expected Manufacturing performance.
• The company repurchased $100M of stock in Q2 and $300M year-to-date, leaving $700M authorized under the $1.0B buyback program.
• The 10-Q says CRL remains a leading non-clinical global drug-development partner with research models, GLP and non-GLP discovery/safety assessment, and manufacturing support across major pharma, biotech, medtech, diagnostics, and government clients.

\[

\Delta \text{Operating income} = 2{,}500 \text{ million} \times 0.01 = 25.0 \text{ million USD}

\]

\[

\frac{\$4,128.4\text{M}}{20{,}000 \text{ employees}} = \$206{,}420 \text{ revenue per employee}

\]

If the employee count is 19,500 instead of 20,000, revenue per employee is approximately $211,713. If the employee count is 21,000, revenue per employee falls to approximately $196,590.

The interpretation is that CRL is a relatively high revenue-per-employee services business. However, revenue per employee alone does not capture segment differences. DSA likely has higher labor intensity per dollar of revenue than Manufacturing Support, while RMS may have more product-like economics.